Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (≤65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial.
暂无分享，去创建一个
C. Flowers | Linghua Wang | Xuelin Huang | K. Patel | P. Jain | R. Kanagal-Shamanna | Shaoying Li | C. Yin | Lei Feng | Sa A. Wang | L. Fayad | J. Westin | P. Lin | S. Thirumurthi | S. Iyer | H. Lee | F. Hagemeister | G. Tang | G. N. Nogueras Gonzalez | L. Medeiros | F. Samaniego | L. Nastoupil | N. Fowler | R. Nair | R. Steiner | N. Wagner-Bartak | C. Ok | M. Badillo | Holly A. Hill | Lucy J. Navsaria | F. Vega | Yixin Yao | Shuangtao Zhao | Guofan Xu | Michael L Wang | D. Santos | Huang Xuelin | J. Jørgensen | Francisco Vega | L. Navsaria | J. Jorgensen | Lei Feng | Michael L. Wang | H. Hill